Опыт применения мангиферина при метаболическом синдроме

Translated title of the contribution: The experience of Mangiferin in metabolic syndrome

Research output: Contribution to journalArticlepeer-review


In this study we investigated the experience of Mangiferin in patient with metabolic syndrome (MS). A total of 20 patients were selected and divided into two groups (the mean age was 50,34±0,9 years), i.e. MS before treatment (BT) and MS with mangiferin treatment at 250 mg orally twice a day for 4 weeks (AT). We analyzed data of lipid profile, coagulogram, liptin, insulin, C-peptid, HbA1c and levels of total immunoglobulins A (IgA), G (Ig G), M (Ig M) in plasma. Mean levels of total cholesterol and low density lipoproteins were significantly higher in patients with MS and BT as compared to MS and AT group (6,20±0,20mmol/l vs 5,70±0,20mmol/l; р<0,05, 3,94±0,20mmol/l vs 3,52±0,20mmol/l; р<0,05 respectively). Mean values of C-peptid was also higher in subjects with MS and BT than in subjects with MS and AT (1221,27±128,40 vs 812,04±122,60 pmol/l; р<0,05). Mean levels of total IgA was significantly higher in patient with MS and AT as compared to MS and BT group (2,52±0,60g/l vs 1,30±0,50g/l (р<0,05). The treatment with Mangiferin was associated with hypolipidemic, immunomodulatoty effects and decline of insulin resistance level in patients with MS.
Translated title of the contributionThe experience of Mangiferin in metabolic syndrome
Original languageRussian
Pages (from-to)44-51
JournalСправочник врача общей практики
Issue number4
StatePublished - 5 Apr 2019




Dive into the research topics of 'The experience of Mangiferin in metabolic syndrome'. Together they form a unique fingerprint.

Cite this